Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study

Abstract

Background and aims

Sulfonylureas are widely used in patients with type 2 diabetes; meanwhile, the increasing fractures risks especially in the old are gradually taken into consideration. This meta-analysis aimed at investigating whether sulfonylureas could influence the risk of fractures in type 2 diabetes (T2DM) in the elder patients (≥ 65 years old).

Methods

We searched the PubMed and other databases to screen eligible studies. Two authors independently extracted data according to the selection criteria for each study. The Newcastle–Ottawa scale was used to evaluate the quality. Subgroups and sensitivity analyses were performed and publication bias was assessed.

Result

A total of 7 studies involving 464,121 individuals were included in our meta-analysis. The pooled risk ratio for developing fracture in sulfonylurea users with type 2 diabetes (≥ 65 years old) was 1.26 (95% CI 1.15–1.39). Sensitivity analyses confirmed the stability of the results and there was no publication bias.

Conclusions

Sulfonylureas could add the risk of fractures among the old with type 2 diabetes. Initial sulfonylureas therapy in both men and women should be done prudently.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Sarodnik C, Bours SPG, Schaper NC et al (2018) The risks of sarcopenia, falls and fractures in patients with type 2 diabetes mellitus. Maturitas 109:70–77

    CAS  Article  Google Scholar 

  2. 2.

    Sircar M, Bhatia A, Munshi M (2016) Review of hypoglycemia in the older adult: clinical implications and management. Can J Diabetes 40:66–72

    Article  Google Scholar 

  3. 3.

    Compston J (2018) Type 2 diabetes mellitus and bone. J Intern Med 283:140–153

    CAS  Article  Google Scholar 

  4. 4.

    Ueda P, Svanström H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365

    Article  Google Scholar 

  5. 5.

    Kalaitzoglou E,  Fowlkes JL, Popescu I,  Thrailkill KM (2019) Diabetes pharmacotherapy and effects on the musculoskeletal system. Diabetes Metab Res Rev 35:e3100

    Article  Google Scholar 

  6. 6.

    Lapane KL, Yang S, Brown MJ et al (2013) Sulfonylureas and risk of falls and fractures: a systematic review. Drugs Aging 30:527–547

    CAS  Article  Google Scholar 

  7. 7.

    Melsen WG, Bootsma MC, Rovers MM, Bonten MJ (2014) The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect 20:123–129

    CAS  Article  Google Scholar 

  8. 8.

    Lapane KL, Jesdale BM, Dubé CE et al (2015) Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus. Diabetes Res Clin Pract 109:411–419

    CAS  Article  Google Scholar 

  9. 9.

    Solomon DH, Cadarette SM, Choudhry NK et al (2009) A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 94:2792–2798

    CAS  Article  Google Scholar 

  10. 10.

    Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731

    Article  Google Scholar 

  11. 11.

    Rajpathak SN, Fu C, Brodovicz KG et al (2015) Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 diabetes. Drugs Aging 32:321–327

    CAS  Article  Google Scholar 

  12. 12.

    Monami M, Cresci B, Colombini A et al (2008) Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 31:199–203

    Article  Google Scholar 

  13. 13.

    Colhoun HM, Livingstone SJ, Looker HC et al (2012) Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55:2929–2937

    CAS  Article  Google Scholar 

  14. 14.

    Pscherer S, Kostev K, Dippel FW, Rathmann W (2016) Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care. Diabetes Metab Syndr Obes 9:17–23

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Thomas MC, Cooper ME, Zimmet P (2016) Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 12:73–81

    CAS  Article  Google Scholar 

  16. 16.

    Zheng Y, Ley SH, Hu FB (2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14:88–98

    Article  Google Scholar 

  17. 17.

    Napoli N, Chandran M, Pierroz DD et al (2017) Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol 13:208–219

    CAS  Article  Google Scholar 

  18. 18.

    Raska I Jr, Rašková M, Zikán V, Škrha J (2017) Prevalence and risk factors of osteoporosis in postmenopausal women with type 2 diabetes mellitus. Cent Eur J Public Health 25:3–10

    Article  Google Scholar 

  19. 19.

    Cacciatore F, Testa G, Galizia G et al (2013) Clinical frailty and long-term mortality in elderly subjects with diabetes. Acta Diabetol 50:251–260

    Article  Google Scholar 

  20. 20.

    Zhu ZN, Jiang YF, Ding T (2014) Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 68:115–123

    CAS  Article  Google Scholar 

  21. 21.

    Chen Q, Liu T, Zhou H et al (2019) Risk of fractures associated with dipeptidyl peptidase-4 inhibitor treatment: a systematic review and meta-analysis of randomized controlled trials. Diabetes Ther 10:1879–1892

    CAS  Article  Google Scholar 

  22. 22.

    Nanjan MJ, Mohammed M, Prashantha Kumar BR, Chandrasekar MJN (2018) Thiazolidinediones as antidiabetic agents: a critical review. Bioorg Chem 77:548–567

    CAS  Article  Google Scholar 

  23. 23.

    Gilbert MP, Pratley RE (2015) The impact of diabetes and diabetes medications on bone health. Endocr Rev 36:194–213

    CAS  Article  Google Scholar 

  24. 24.

    Driessen JH, van den Bergh JP, van Onzenoort HA et al (2017) Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: a retrospective population-based cohort study. Diabetes Obes Metab 19:421–428

    CAS  Article  Google Scholar 

  25. 25.

    Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149

    Article  Google Scholar 

  26. 26.

    Douros A, Yin H, Yu OHY et al (2017) Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events. Diabetes Care 40:1506–1513

    CAS  Article  Google Scholar 

  27. 27.

    Yu O, Azoulay L, Yin H et al (2018) Sulfonylureas as Initial treatment for type 2 diabetes and the risk of severe hypoglycemia. Am J Med 131:317.e11–317.e22

    Article  Google Scholar 

  28. 28.

    Jackuliak P, Kuzma M, Payer J (2019) Effect of antidiabetic treatment on bone. Physiol Res 68:S107-s120

    CAS  Article  Google Scholar 

Download references

Funding

This research was done without receiving any funding from other institutions.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Zhen Zhang.

Ethics declarations

Conflict of interest

The authors declare that there are no financial interests or personal relationships to affect the result of this paper. All the authors have admitted the final manuscript.

Ethical approval

This article is also not performed with human or animals by any of the authors.

Informed consent

This paper did not contain human participants enrolled by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tao, Y., E, M., Shi, J. et al. Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study. Aging Clin Exp Res (2020). https://doi.org/10.1007/s40520-020-01736-4

Download citation

Keywords

  • Sulfonylureas
  • Type 2 diabetes
  • Fracture risk
  • Elder people
  • Meta-analysis